Literature DB >> 23822179

Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors.

Guillermo Moreno-Sanz1, Andrea Duranti, Laurin Melzig, Claudio Fiorelli, Gian Filippo Ruda, Giampiero Colombano, Paola Mestichelli, Silvano Sanchini, Andrea Tontini, Marco Mor, Tiziano Bandiera, Rita Scarpelli, Giorgio Tarzia, Daniele Piomelli.   

Abstract

The peripherally restricted fatty acid amide hydrolase (FAAH) inhibitor URB937 (3, cyclohexylcarbamic acid 3'-carbamoyl-6-hydroxybiphenyl-3-yl ester) is extruded from the brain and spinal cord by the Abcg2 efflux transporter. Despite its inability to enter the central nervous system (CNS), 3 exerts profound antinociceptive effects in mice and rats, which result from the inhibition of FAAH in peripheral tissues and the consequent enhancement of anandamide signaling at CB1 cannabinoid receptors localized on sensory nerve endings. In the present study, we examined the structure-activity relationships (SAR) for the biphenyl region of compound 3, focusing on the carbamoyl and hydroxyl groups in the distal and proximal phenyl rings. Our SAR studies generated a new series of peripherally restricted FAAH inhibitors and identified compound 35 (cyclohexylcarbamic acid 3'-carbamoyl-5-hydroxybiphenyl-3-yl ester) as the most potent brain-impermeant FAAH inhibitor disclosed to date.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23822179      PMCID: PMC4062305          DOI: 10.1021/jm4007017

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  27 in total

1.  Oxidative cleavage of 1,3-dicarbonyls to carboxylic acids with oxone.

Authors:  S W Ashford; K C Grega
Journal:  J Org Chem       Date:  2001-02-23       Impact factor: 4.354

2.  Identification of productive inhibitor binding orientation in fatty acid amide hydrolase (FAAH) by QM/MM mechanistic modelling.

Authors:  Alessio Lodola; Marco Mor; Silvia Rivara; Christo Christov; Giorgio Tarzia; Daniele Piomelli; Adrian J Mulholland
Journal:  Chem Commun (Camb)       Date:  2007-10-19       Impact factor: 6.222

3.  Exploiting transport activity of p-glycoprotein at the blood-brain barrier for the development of peripheral cannabinoid type 1 receptor antagonists.

Authors:  Hanneke G M Wittgen; Rick Greupink; Jeroen J M W van den Heuvel; Petra H H van den Broek; Heike Dinter-Heidorn; Jan B Koenderink; Frans G M Russel
Journal:  Mol Pharm       Date:  2012-03-28       Impact factor: 4.939

Review 4.  The endocannabinoid system and the brain.

Authors:  Raphael Mechoulam; Linda A Parker
Journal:  Annu Rev Psychol       Date:  2012-07-12       Impact factor: 24.137

5.  ABCG2 transports sulfated conjugates of steroids and xenobiotics.

Authors:  Michiko Suzuki; Hiroshi Suzuki; Yoshikazu Sugimoto; Yuichi Sugiyama
Journal:  J Biol Chem       Date:  2003-04-07       Impact factor: 5.157

6.  Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

Authors:  John D Allen; Arnold van Loevezijn; Jeany M Lakhai; Martin van der Valk; Olaf van Tellingen; Glen Reid; Jan H M Schellens; Gerrit-Jan Koomen; Alfred H Schinkel
Journal:  Mol Cancer Ther       Date:  2002-04       Impact factor: 6.261

7.  Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors.

Authors:  Nitin Agarwal; Pal Pacher; Irmgard Tegeder; Fumimasa Amaya; Cristina E Constantin; Gary J Brenner; Tiziana Rubino; Christoph W Michalski; Giovanni Marsicano; Krisztina Monory; Ken Mackie; Claudiu Marian; Sandor Batkai; Daniela Parolaro; Michael J Fischer; Peter Reeh; George Kunos; Michaela Kress; Beat Lutz; Clifford J Woolf; Rohini Kuner
Journal:  Nat Neurosci       Date:  2007-06-10       Impact factor: 24.884

8.  Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice.

Authors:  Jesse LoVerme; Andrea Duranti; Andrea Tontini; Gilberto Spadoni; Marco Mor; Silvia Rivara; Nephi Stella; Cong Xu; Giorgio Tarzia; Daniele Piomelli
Journal:  Bioorg Med Chem Lett       Date:  2008-12-24       Impact factor: 2.823

9.  Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability.

Authors:  Federica Vacondio; Claudia Silva; Alessio Lodola; Alessandro Fioni; Silvia Rivara; Andrea Duranti; Andrea Tontini; Silvano Sanchini; Jason R Clapper; Daniele Piomelli; Marco Mor; Giorgio Tarzia
Journal:  ChemMedChem       Date:  2009-09       Impact factor: 3.466

10.  Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity.

Authors:  Alan Fulp; Katherine Bortoff; Herbert Seltzman; Yanan Zhang; James Mathews; Rodney Snyder; Tim Fennell; Rangan Maitra
Journal:  J Med Chem       Date:  2012-03-09       Impact factor: 7.446

View more
  7 in total

1.  Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.

Authors:  Sean D Kodani; Saavan Bhakta; Sung Hee Hwang; Svetlana Pakhomova; Marcia E Newcomer; Christophe Morisseau; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2018-01-04       Impact factor: 2.823

2.  Pharmacokinetics, pharmacodynamics and safety studies on URB937, a peripherally restricted fatty acid amide hydrolase inhibitor, in rats.

Authors:  Valentina Vozella; Faizy Ahmed; Paoula Choobchian; Collin B Merrill; Cristina Zibardi; Giorgio Tarzia; Marco Mor; Andrea Duranti; Andrea Tontini; Silvia Rivara; Daniele Piomelli
Journal:  J Pharm Pharmacol       Date:  2019-10-03       Impact factor: 3.765

3.  Inhibition of fatty acid amide hydrolase in the CNS prevents and reverses morphine tolerance in male and female mice.

Authors:  Yannick Fotio; Francesca Palese; Pablo Guaman Tipan; Faizy Ahmed; Daniele Piomelli
Journal:  Br J Pharmacol       Date:  2020-03-30       Impact factor: 9.473

4.  Structural determinants of peripheral O-arylcarbamate FAAH inhibitors render them dual substrates for Abcb1 and Abcg2 and restrict their access to the brain.

Authors:  Guillermo Moreno-Sanz; Borja Barrera; Andrea Armirotti; Sine M Bertozzi; Rita Scarpelli; Tiziano Bandiera; Julio G Prieto; Andrea Duranti; Giorgio Tarzia; Gracia Merino; Daniele Piomelli
Journal:  Pharmacol Res       Date:  2014-06-30       Impact factor: 7.658

5.  A Primary Cortical Input to Hippocampus Expresses a Pathway-Specific and Endocannabinoid-Dependent Form of Long-Term Potentiation.

Authors:  Weisheng Wang; Brian H Trieu; Linda C Palmer; Yousheng Jia; Danielle T Pham; Kwang-Mook Jung; Carley A Karsten; Collin B Merrill; Ken Mackie; Christine M Gall; Daniele Piomelli; Gary Lynch
Journal:  eNeuro       Date:  2016-08-08

6.  Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors.

Authors:  Sean D Kodani; Debin Wan; Karen M Wagner; Sung Hee Hwang; Christophe Morisseau; Bruce D Hammock
Journal:  ACS Omega       Date:  2018-10-25

Review 7.  Can You Pass the Acid Test? Critical Review and Novel Therapeutic Perspectives of Δ9-Tetrahydrocannabinolic Acid A.

Authors:  Guillermo Moreno-Sanz
Journal:  Cannabis Cannabinoid Res       Date:  2016-06-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.